Ophthalmology Clinical Trials
The University of Virginia Department Of Ophthalmology faculty members conduct their own research to investigate new treatment options for ophthalmic diseases and conditions. The department is actively involved in many sponsored clinical trials to test new ophthalmic procedures and treatments. In recent years, the department has participated in clinical trials to investigate new treatments for diabetic macular edema, geographic atrophy, and neovascular age-related macular degeneration. Additionally, the department is investigating screening retinopathy of prematurity with RetiVue wide-field imaging.
The Department of Ophthalmology is currently conducting the following Clinical Trials. For more information, please email our clinical research coordinator Ashton Leone, MPH at email@example.com.
Current Clinical Trials
RHONE Study-A Multicenter, Open-label Extension Study to Evaluate the Long Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema.
Sponsor: F. Hoffman-La Roche; Principal Investigator: Paul Yates MD, PhD
ARCHER Study-A Phase 2, Multicenter, Parallel-Group, Double-Masked 4-Arm, Sham-Controlled Study of the Efficacy, Safety and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Sponsor: Annexon Inc; Principal Investigator: Michael Cusick, MD
GALE Study-A Phase 3, Open Label, Multicenter Extension Study to Evaluate the Long Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Sponsor: Apellis Pharmaceuticals; Principal Investigator: Paul Yates, MD, PhD
Actively Recruiting Subjects
RetiVue Wide-Field Retinopathy of Prematurity Screening
Sponsor: RetiVue; Principal Investigator: Peter Netland, MD, PhD
Neovascular Age-Related Macular Degeneration
SHORE Study-A Phase 3, Multicenter, Double-Masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-Related Macular Degeneration.
Sponsor: Opthea; Principal Investigator: Michael Cusick, MD